Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Australian medtech firm Orthocell recorded its strongest U.S. month for Remplir™, selling 92 units in October 2026.
Orthocell Ltd reported its highest single-month U.S. sales figures since the commercial launch of Remplir™, its FDA-cleared collagen nerve wrap, with 92 units sold in October 2026. The milestone signals growing traction for the Australian medical device maker in one of the world's most competitive healthcare markets.
Remplir™ is engineered to support the repair and protection of peripheral nerves, a clinical segment that has drawn increasing attention as surgeons seek alternatives to traditional nerve repair techniques. The device is designed and manufactured in Australia, and Orthocell has positioned it as a contender for category leadership in key international markets.
Read more Mumtalakat and ARP Group Plan AI-Native Wholesale Bank in Bahrain →
The October performance represents a meaningful commercial inflection point for the company, which has been working to expand its U.S. footprint since receiving FDA clearance. Sustained monthly growth in unit sales would be a key indicator of whether the product can achieve the scale needed to compete in the broader peripheral nerve repair market.
Orthocell's progress with Remplir™ comes as the global nerve repair and regeneration sector continues to attract investment and innovation. The company's ability to manufacture a differentiated collagen-based product in Australia and distribute it competitively in the U.S. underscores the international ambitions of smaller medtech players operating outside traditional hubs.
Continue reading at All Financial Services & Investing.
